Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aphton (apht) -- Ignore unavailable to you. Want to Upgrade?

To: mason630 who wrote (60)	4/10/1998 4:03:00 PM
From: rocket	Read Replies (1) \| Respond to of 95

Actually, I was a bit surprised as I wasn't aware that they were into genomes and such. I suspect that it gives us some insight into the quality and depth of the work that Aphton is getting into. I was even more ecstatic about the recent findings re: breast ca and Tamoxifen as I believe ultimately, Aphton's rx for breast ca will be shown to be every bit as effective as Tamoxifen, but without increased uterine ca risk and other side effects that Tamoxifen has. I'm hoping we'll hear some news about another alliance with a big pharma soon. Hang in there.